benzbromarone has been researched along with Gout in 131 studies
Benzbromarone: Uricosuric that acts by increasing uric acid clearance. It is used in the treatment of gout.
benzbromarone : 1-Benzofuran substituted at C-2 and C-3 by an ethyl group and a 3,5-dibromo-4-hydroxybenzoyl group respectively. An inhibitor of CYP2C9, it is used as an anti-gout medication.
Gout: Metabolic disorder characterized by recurrent acute arthritis, hyperuricemia and deposition of sodium urate in and around the joints, sometimes with formation of URIC ACID calculi.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The predominant mechanism driving hyperuricemia in gout is renal uric acid underexcretion; however, the standard urate-lowering therapy (ULT) recommendation is first-line xanthine oxidase inhibitor (XOI), irrespective of the cause of hyperuricemia." | 9.51 | Superiority of Low-Dose Benzbromarone to Low-Dose Febuxostat in a Prospective, Randomized Comparative Effectiveness Trial in Gout Patients With Renal Uric Acid Underexcretion. ( Chen, Y; Cheng, X; Cui, L; Dalbeth, N; He, Y; Hu, S; Ji, A; Li, C; Li, H; Liu, Z; Lu, J; Ma, L; Qi, H; Ran, Z; Sun, M; Terkeltaub, R; Wang, C; Xue, X; Yan, F; Yu, Q; Yuan, X, 2022) |
| "To compare the efficacy and safety of citrate mixture and sodium bicarbonate on urine alkalization in gout patients under benzbromarone treatment." | 9.41 | The efficacy and safety of citrate mixture vs sodium bicarbonate on urine alkalization in Chinese primary gout patients with benzbromarone: a prospective, randomized controlled study. ( Chen, Y; Cui, L; He, Y; Ji, A; Ji, X; Jia, Z; Li, C; Li, X; Liu, Z; Lu, J; Merriman, TR; Ren, W; Sun, R; Sun, W; Wang, C; Wang, X; Xue, X; Zhang, H, 2021) |
| "Dotinurad 2 mg was verified to have a non-inferior serum uric acid lowering effect compared with benzbromarone 50 mg, in Japanese hyperuricemic patients with or without gout." | 9.34 | Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study. ( Fushimi, M; Hosoya, T; Ohashi, T; Sano, T; Sasaki, T, 2020) |
| "To compare the efficacy and safety of low-dose febuxostat with low-dose benzbromarone in patients with primary gout, a randomized controlled, open-label trial was performed among male patients with primary gout for urate-lowering therapy (ULT) in a dedicated gout clinic in China." | 9.30 | Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort. ( Cheng, X; Cui, L; He, Y; Ji, A; Li, C; Li, H; Liang, N; Ma, L; Sun, M; Sun, R; Sun, W; Wang, C; Wu, X; Xu, T; Xue, X; Yuan, X; Zhang, H, 2019) |
| "Japanese male subjects aged 21-65 years with gout (n = 37) or asymptomatic hyperuricaemia (n = 35) and serum urate (sUA) ⩾8 mg/dl were randomized to febuxostat (10, 20, 40 mg) in combination with verinurad (2." | 9.27 | Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study. ( Gillen, M; Hall, J; Ito, Y; Liu, S; Shen, Z; Shiramoto, M; Yamamoto, A; Yan, X, 2018) |
| " Cox proportional hazard ratio was used to compare the risk of CAD in gout patients taking allopurinol or/and benzbromarone with those taking neither drug." | 9.24 | Allopurinol, benzbromarone and risk of coronary heart disease in gout patients: A population-based study. ( Chiang, SJ; Daimon, M; Ho, Y; Lin, HC; Uang, YS; Wang, CH; Wang, LH, 2017) |
| "We aimed to assess the relative efficacy and safety of dotinurad (2 mg), benzbromarone (50 mg), and febuxostat (40 mg) in hyperuricemic patients with or without gout." | 9.22 | Comparative efficacy and safety of dotinurad, febuxostat, and benzbromarone in hyperuricemic patients with or without gout: A network meta-analysis of randomized controlled trials. ( Lee, YH; Song, GG, 2022) |
| "Log serum CRP levels were not significantly different between the patients with gout and healthy subjects, while log serum CRP levels were decreased by 11% after benzbromarone treatment, as compared to the values before treatment (p < 0." | 9.15 | Serum CRP in patients with gout and effects of benzbromarone. ( Koyama, H; Kurajoh, M; Moriwaki, Y; Okuda, C; Tsutsumi, Z; Yamamoto, A; Yamamoto, T, 2011) |
| "To investigate the efficacy and tolerability of allopurinol as the first-choice antihyperuricaemic treatment for gout, and compare the efficacy and tolerability of benzbromarone and probenecid as second-choice treatment." | 9.14 | Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. ( Brouwers, JR; Delsing, J; Griep, EN; Hoekstra, M; Jansen, TL; Reinders, MK; van de Laar, MA; van Roon, EN, 2009) |
| "Benzbromarone is effective in lowering uric acid levels and in reducing the number of acute attacks of gout in patients who have failed optimal treatment." | 9.11 | Benzbromarone therapy in management of refractory gout. ( Gow, P; Kumar, S; Ng, J, 2005) |
| "To study the efficacy of allopurinol and benzbromarone to reduce serum urate concentrations in patients with primary chronic gout." | 9.08 | Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. ( Alonso-Ruiz, A; Calabozo, M; García-Erauskin, G; Herrero-Beites, A; Perez-Ruiz, F; Ruiz-Lucea, E, 1998) |
| "The objectives of this study were to establish if, and to what extent, benzbromarone affects allopurinol/oxypurinol kinetics, and to compare the uric acid lowering capabilities of Allomaron (allopurinol 100 mg plus benzbromarone 20 mg) with the effects of allopurinol alone in patients with confirmed gout." | 9.07 | The effect of benzbromarone on allopurinol/oxypurinol kinetics in patients with gout. ( Groenewoud, G; Hundt, HK; Müller, FO; Schall, R; van der Merwe, JC; van Dyk, M, 1993) |
| "Benzbromarone is a uricosuric drug that has been used in the treatment of gout over the last 30 years." | 9.01 | Benzbromarone in the treatment of gout. ( Azevedo, VF; da Rocha Castelar Pinheiro, G; Dos Santos Paiva, E; Kos, IA; Vargas-Santos, AB, 2019) |
| "Our review found low- to moderate-quality evidence indicating similar effects on withdrawals due to AEs and SAEs and incidence of acute gout attacks when allopurinol (100 to 600 mg daily) was compared with placebo, benzbromarone (100 to 200 mg daily) or febuxostat (80 mg daily)." | 8.90 | Allopurinol for chronic gout. ( Bombardier, C; Buchbinder, R; Edwards, CJ; Kydd, AS; Seth, R, 2014) |
| "Benzbromarone1 is a benzofuran derivative which lowers serum urate and increases urinary urate excretion in normal, hyperuricaemic and gouty subjects." | 8.75 | Benzbromarone: a review of its pharmacological properties and therapeutic use in gout and hyperuricaemia. ( Avery, GS; Brogden, RN; Heel, RC; Speight, TM, 1977) |
| " This research aimed to study the relation of ischemic cerebrovascular disease with benzbromarone use among persons with gout-related disorders." | 8.31 | The risk of ischemic cerebrovascular disease associated with benzbromarone use in gout people: A retrospective cohort study in Taiwan. ( Hwang, BF; Kuo, YH; Lai, SW; Liao, KF; Liu, CS, 2023) |
| "Using the Korean National Health Insurance claims data (2002-17), we conducted a cohort study of 124 434 gout patients who initiated either allopurinol (n = 103 695) or benzbromarone (n = 20 739), matched on propensity score at a 5:1 ratio." | 8.02 | Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout. ( Kang, EH; Kim, SC; Park, EH; Shin, A; Song, JS, 2021) |
| "To investigate the effects on hypercholesterolemia and hypertriglyceridemia in gouty patients receiving uric acid-lowering therapy (UALT)." | 7.91 | Efficacy of uric acid-lowering therapy on hypercholesterolemia and hypertriglyceridemia in gouty patients. ( Deng, JX; Jie, LG; Qu, Y; Wu, J; Yu, QH; Zhang, YP, 2019) |
| " Considering the increased prevalence of diabetes mellitus (DM) in the gout population, this study evaluated the effects of benzbromarone, a uricosuric agent, on the incidence of DM in the gout population." | 7.88 | Decreased incidence of diabetes in patients with gout using benzbromarone. ( Chang, KT; Chang, YH; Chiu, YW; Hung, CC; Hwang, SJ; Kuo, IC; Lin, HY; Lin, SF; Niu, SW; Ta, A, 2018) |
| "To evaluate and compare the safety and efficacy of three urate lowering agents: febuxostat, allopurinol, and benzbromarone, when used to treat Chinese gout patients." | 7.85 | A study comparing the safety and efficacy of febuxostat, allopurinol, and benzbromarone in Chinese gout patients: a retrospective cohort study . ( Chen, X; Su, J; Tian, J; Zhou, Q; Zhou, T; Zhu, J, 2017) |
| "Benzbromarone provides useful urate-lowering efficacy and does not appear unsafe in patients with gout." | 7.83 | The safety and efficacy of benzbromarone in gout in Aotearoa New Zealand. ( Cathro, A; Corkill, M; Dalbeth, N; Frampton, C; Gardner, D; Grainger, R; Haslett, J; Kain, T; Kumar, R; Kumar, S; Metcalfe, S; Porter, D; Stamp, LK; Stebbings, S; Taylor, G; White, D; Wyeth, J, 2016) |
| "The object of this study was to evaluate the effect of uric acid lowering therapy in reducing the new development of comorbidities and the frequency of acute attacks in gout patients." | 7.80 | Prevention of comorbidity and acute attack of gout by uric acid lowering therapy. ( Joo, H; Joo, K; Jung, KH; Kwon, SR; Lim, MJ; Park, W, 2014) |
| "Prospective CYP2C9 genotyping of Caucasian gout patients may be warranted for benzbromarone, whereas the low frequencies of CYP2C9 PM alleles in Polynesians suggests that the CYP2C9 polymorphism may be of little or no relevance to benzbromarone prescribing in this population." | 7.80 | Frequency of CYP2C9 polymorphisms in Polynesian people and potential relevance to management of gout with benzbromarone. ( Black, MA; Cadzow, M; Dalbeth, N; Harrison, AA; Jones, PB; Merriman, TR; Roberts, RL; Stamp, LK; Wallace, MC; Wright, DF, 2014) |
| "Although hyperuricemia is suggested to increase allantoin production in both pro- and antioxidant manners, it remains undetermined whether it increases the serum concentration of allantoin." | 7.78 | Relationship between serum allantoin and urate in healthy subjects and effects of benzbromarone in gout patients. ( Koga, M; Koyama, H; Kurajoh, M; Moriwaki, Y; Shoji, T; Sumida, C; Tsutsumi, Z; Yamamoto, A; Yamamoto, T, 2012) |
| "A study was conducted to determine whether combination treatment using allopurinol and benzbromarone was more useful than single allopurinol treatment for the gout and hyperuricemia accompanying renal dysfunction." | 7.74 | [Usefulness of combination treatment using allopurinol and benzbromarone for gout and hyperuricemia accompanying renal dysfunction: kinetic analysis of oxypurinol]. ( Gomi, H; Hikita, M; Hosoya, T; Ichida, K; Ohno, I; Okabe, H; Saikawa, H; Uetake, D; Yamaguchi, Y, 2008) |
| "Lasting normalisation of uric acid levels after treatment of patients with gout and hyperuricaemia with a combination of 300 mg allopurinol and 60 mg benzbromarone A total of 210 patients (163 men, 47 women) with gout and hyperuricaemia was treated for three months with daily doses of 300 mg allopurinol and 60 mg benzbromarone." | 7.68 | [Long lasting normalization of uric acid after combination therapy with 300 mg allopurinol and 60 mg benzbromarone in patients with gout and hyperuricemia]. ( Matzkies, F, 1992) |
| "The results over 10 years in 200 patients (103 with gout and 97 with hyperuricaemia) treated with benzbromarone 75 - 120 mg/d are reported." | 7.66 | Ten years' experience with benzbromarone in the management of gout and hyperuricaemia. ( Giudicelli, CP; Masbernard, A, 1981) |
"Treatment with benzbromarone monotherapy (range: 100-200 mg/day; mean 138 mg/day) resulted in 92% of patients reaching target levels sUr | 6.73 | Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients. ( Brouwers, JR; Houtman, PM; Jansen, TL; Reinders, MK; van Roon, EN, 2007) | |
| "The predominant mechanism driving hyperuricemia in gout is renal uric acid underexcretion; however, the standard urate-lowering therapy (ULT) recommendation is first-line xanthine oxidase inhibitor (XOI), irrespective of the cause of hyperuricemia." | 5.51 | Superiority of Low-Dose Benzbromarone to Low-Dose Febuxostat in a Prospective, Randomized Comparative Effectiveness Trial in Gout Patients With Renal Uric Acid Underexcretion. ( Chen, Y; Cheng, X; Cui, L; Dalbeth, N; He, Y; Hu, S; Ji, A; Li, C; Li, H; Liu, Z; Lu, J; Ma, L; Qi, H; Ran, Z; Sun, M; Terkeltaub, R; Wang, C; Xue, X; Yan, F; Yu, Q; Yuan, X, 2022) |
| "To compare the efficacy and safety of citrate mixture and sodium bicarbonate on urine alkalization in gout patients under benzbromarone treatment." | 5.41 | The efficacy and safety of citrate mixture vs sodium bicarbonate on urine alkalization in Chinese primary gout patients with benzbromarone: a prospective, randomized controlled study. ( Chen, Y; Cui, L; He, Y; Ji, A; Ji, X; Jia, Z; Li, C; Li, X; Liu, Z; Lu, J; Merriman, TR; Ren, W; Sun, R; Sun, W; Wang, C; Wang, X; Xue, X; Zhang, H, 2021) |
| "Dotinurad 2 mg was verified to have a non-inferior serum uric acid lowering effect compared with benzbromarone 50 mg, in Japanese hyperuricemic patients with or without gout." | 5.34 | Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study. ( Fushimi, M; Hosoya, T; Ohashi, T; Sano, T; Sasaki, T, 2020) |
| "To compare the efficacy and safety of low-dose febuxostat with low-dose benzbromarone in patients with primary gout, a randomized controlled, open-label trial was performed among male patients with primary gout for urate-lowering therapy (ULT) in a dedicated gout clinic in China." | 5.30 | Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort. ( Cheng, X; Cui, L; He, Y; Ji, A; Li, C; Li, H; Liang, N; Ma, L; Sun, M; Sun, R; Sun, W; Wang, C; Wu, X; Xu, T; Xue, X; Yuan, X; Zhang, H, 2019) |
| "Benzbromarone treatment, 50-100 mg daily, led to a parallel decrease of serum lipids and uric acid." | 5.28 | [The effect of benzbromarone on hyperlipidemia in gout]. ( Kŭnev, K; Marinchev, L, 1990) |
| "Japanese male subjects aged 21-65 years with gout (n = 37) or asymptomatic hyperuricaemia (n = 35) and serum urate (sUA) ⩾8 mg/dl were randomized to febuxostat (10, 20, 40 mg) in combination with verinurad (2." | 5.27 | Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study. ( Gillen, M; Hall, J; Ito, Y; Liu, S; Shen, Z; Shiramoto, M; Yamamoto, A; Yan, X, 2018) |
| " Cox proportional hazard ratio was used to compare the risk of CAD in gout patients taking allopurinol or/and benzbromarone with those taking neither drug." | 5.24 | Allopurinol, benzbromarone and risk of coronary heart disease in gout patients: A population-based study. ( Chiang, SJ; Daimon, M; Ho, Y; Lin, HC; Uang, YS; Wang, CH; Wang, LH, 2017) |
| "We aimed to assess the relative efficacy and safety of dotinurad (2 mg), benzbromarone (50 mg), and febuxostat (40 mg) in hyperuricemic patients with or without gout." | 5.22 | Comparative efficacy and safety of dotinurad, febuxostat, and benzbromarone in hyperuricemic patients with or without gout: A network meta-analysis of randomized controlled trials. ( Lee, YH; Song, GG, 2022) |
| "To investigate the efficacy and tolerability of allopurinol as the first-choice antihyperuricaemic treatment for gout, and compare the efficacy and tolerability of benzbromarone and probenecid as second-choice treatment." | 5.14 | Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. ( Brouwers, JR; Delsing, J; Griep, EN; Hoekstra, M; Jansen, TL; Reinders, MK; van de Laar, MA; van Roon, EN, 2009) |
| "When treating gout patients, we have incidentally found elevated serum levels of adiponectin in some after administration of benzbromarone." | 5.14 | Effects of benzbromarone and allopurinol on adiponectin in vivo and in vitro. ( Inokuchi, T; Ka, T; Masuzaki, H; Moriwaki, Y; Takahashi, S; Tsutsumi, Z; Yamamoto, A; Yamamoto, T, 2009) |
| "Benzbromarone is effective in lowering uric acid levels and in reducing the number of acute attacks of gout in patients who have failed optimal treatment." | 5.11 | Benzbromarone therapy in management of refractory gout. ( Gow, P; Kumar, S; Ng, J, 2005) |
| "Sixty-three patients with crystal-confirmed tophaceous gout were treated with allopurinol, benzbromarone, or combined therapy to achieve serum uric acid levels less than the threshold for saturation of urate in tissues." | 5.10 | Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. ( Calabozo, M; Herrero-Beites, AM; Perez-Ruiz, F; Pijoan, JI; Ruibal, A, 2002) |
| "To study the efficacy of allopurinol and benzbromarone to reduce serum urate concentrations in patients with primary chronic gout." | 5.08 | Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. ( Alonso-Ruiz, A; Calabozo, M; García-Erauskin, G; Herrero-Beites, A; Perez-Ruiz, F; Ruiz-Lucea, E, 1998) |
| "To investigate whether allopurinol and benzbromarone affect the concentration of uridine in plasma, allopurinol or benzbromarone were administered to patients with gout for 3 to 6 months." | 5.08 | Effect of allopurinol and benzbromarone on the concentration of uridine in plasma. ( Higashino, K; Moriwaki, Y; Takahashi, S; Tsutsumi, Z; Yamakita, J; Yamamoto, T, 1997) |
| "The objectives of this study were to establish if, and to what extent, benzbromarone affects allopurinol/oxypurinol kinetics, and to compare the uric acid lowering capabilities of Allomaron (allopurinol 100 mg plus benzbromarone 20 mg) with the effects of allopurinol alone in patients with confirmed gout." | 5.07 | The effect of benzbromarone on allopurinol/oxypurinol kinetics in patients with gout. ( Groenewoud, G; Hundt, HK; Müller, FO; Schall, R; van der Merwe, JC; van Dyk, M, 1993) |
| "Benzbromarone is a uricosuric drug that has been used in the treatment of gout over the last 30 years." | 5.01 | Benzbromarone in the treatment of gout. ( Azevedo, VF; da Rocha Castelar Pinheiro, G; Dos Santos Paiva, E; Kos, IA; Vargas-Santos, AB, 2019) |
| "Over the last 70 years, pharmacotherapy in gout with urate-lowering drugs has consisted of four drugs only: In 1952, a mild uricosuric probenecid became available, the xanthine oxidase inhibitor Allopurinol in 1964, and the latter became the most frequently used urate-lowering drug worldwide; in the Eurozone, the uricosuric benzbromarone was welcomed in 1977." | 4.98 | International position paper on the appropriate use of uricosurics with the introduction of lesinurad. ( Jansen, TL; Perez-Ruiz, F; Richette, P; Tausche, AK, 2018) |
| "Our review found low- to moderate-quality evidence indicating similar effects on withdrawals due to AEs and SAEs and incidence of acute gout attacks when allopurinol (100 to 600 mg daily) was compared with placebo, benzbromarone (100 to 200 mg daily) or febuxostat (80 mg daily)." | 4.90 | Allopurinol for chronic gout. ( Bombardier, C; Buchbinder, R; Edwards, CJ; Kydd, AS; Seth, R, 2014) |
| "We considered all randomised controlled trials (RCTs) or quasi-randomised controlled trials (controlled clinical trials (CCTs)) that compared uricosuric medications (benzbromarone, probenecid or sulphinpyrazone) alone or in combination with another therapy (placebo or other active uric acid-lowering medication, or non-pharmacological treatment) in adults with chronic gout for inclusion." | 4.90 | Uricosuric medications for chronic gout. ( Bombardier, C; Buchbinder, R; Edwards, CJ; Kydd, AS; Seth, R, 2014) |
| "Urate lowering treatment is indicated in patients with recurrent acute attacks, tophi, gouty arthropathy, radiographic changes of gout, multiple joint involvement, or associated uric acid nephrolithiasis." | 4.84 | [Uricosuric agent]. ( Ohno, I, 2008) |
| "Benzbromarone1 is a benzofuran derivative which lowers serum urate and increases urinary urate excretion in normal, hyperuricaemic and gouty subjects." | 4.75 | Benzbromarone: a review of its pharmacological properties and therapeutic use in gout and hyperuricaemia. ( Avery, GS; Brogden, RN; Heel, RC; Speight, TM, 1977) |
| " This research aimed to study the relation of ischemic cerebrovascular disease with benzbromarone use among persons with gout-related disorders." | 4.31 | The risk of ischemic cerebrovascular disease associated with benzbromarone use in gout people: A retrospective cohort study in Taiwan. ( Hwang, BF; Kuo, YH; Lai, SW; Liao, KF; Liu, CS, 2023) |
| "Lesinurad is a uricosuric agent for the treatment of hyperuricemia associated with gout, which was found lacking in efficacy and safety." | 4.12 | Discovery of Novel Bicyclic Imidazolopyridine-Containing Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Improved Efficacy and Favorable Druggability. ( Ji, J; Liang, R; Liao, H; Liu, X; Pang, J; Shi, X; Tao, Y; Wu, T; Zhan, P; Zhang, J; Zhang, Z; Zhao, F; Zhao, T, 2022) |
| "Using the Korean National Health Insurance claims data (2002-17), we conducted a cohort study of 124 434 gout patients who initiated either allopurinol (n = 103 695) or benzbromarone (n = 20 739), matched on propensity score at a 5:1 ratio." | 4.02 | Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout. ( Kang, EH; Kim, SC; Park, EH; Shin, A; Song, JS, 2021) |
| "Lesinurad, a human urate transporter 1 (URAT1) inhibitor approved as a medication for the treatment of hyperuricemia associated with gout in 2015, can cause liver and renal toxicity." | 3.96 | Novel Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Favorable Druggability. ( Ai, W; Chen, Y; Dong, Y; Kang, D; Liang, R; Liu, X; Meng, Q; Pang, J; Sun, Z; Wu, T; Zhan, P; Zhao, T; Zhao, Z, 2020) |
| "To investigate the effects on hypercholesterolemia and hypertriglyceridemia in gouty patients receiving uric acid-lowering therapy (UALT)." | 3.91 | Efficacy of uric acid-lowering therapy on hypercholesterolemia and hypertriglyceridemia in gouty patients. ( Deng, JX; Jie, LG; Qu, Y; Wu, J; Yu, QH; Zhang, YP, 2019) |
| "To assess the effects of colchicine, allopurinol and benzbromarone on the risk of cataract in patients with gout." | 3.91 | Association of gout medications and risk of cataract: a population-based case-control study. ( Li, YJ; Perng, WT; Tseng, KY; Wang, YH; Wei, JC, 2019) |
| " Considering the increased prevalence of diabetes mellitus (DM) in the gout population, this study evaluated the effects of benzbromarone, a uricosuric agent, on the incidence of DM in the gout population." | 3.88 | Decreased incidence of diabetes in patients with gout using benzbromarone. ( Chang, KT; Chang, YH; Chiu, YW; Hung, CC; Hwang, SJ; Kuo, IC; Lin, HY; Lin, SF; Niu, SW; Ta, A, 2018) |
| "To evaluate and compare the safety and efficacy of three urate lowering agents: febuxostat, allopurinol, and benzbromarone, when used to treat Chinese gout patients." | 3.85 | A study comparing the safety and efficacy of febuxostat, allopurinol, and benzbromarone in Chinese gout patients: a retrospective cohort study . ( Chen, X; Su, J; Tian, J; Zhou, Q; Zhou, T; Zhu, J, 2017) |
| "Benzbromarone (BBR) is effective in the treatment of gout; however, clinical findings have shown it can also cause fatal hepatic failure." | 3.85 | Metabolic Epoxidation Is a Critical Step for the Development of Benzbromarone-Induced Hepatotoxicity. ( Lan, Q; Pang, J; Peng, Y; Wang, H; Wang, S; Wang, W; Wang, X; Zhang, T; Zhao, H; Zhao, Y; Zheng, J, 2017) |
| "Gout is caused by elevated serum urate levels, which can be treated using inhibitors of the uric acid transporter, URAT1." | 3.85 | Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout. ( Gunic, E; Liu, S; Miner, JN; Tan, PK, 2017) |
| "Benzbromarone provides useful urate-lowering efficacy and does not appear unsafe in patients with gout." | 3.83 | The safety and efficacy of benzbromarone in gout in Aotearoa New Zealand. ( Cathro, A; Corkill, M; Dalbeth, N; Frampton, C; Gardner, D; Grainger, R; Haslett, J; Kain, T; Kumar, R; Kumar, S; Metcalfe, S; Porter, D; Stamp, LK; Stebbings, S; Taylor, G; White, D; Wyeth, J, 2016) |
| "The purpose of this study is to investigate the effect of urate-lowering therapies (ULTs) on renal uric acid excretion in gout patients." | 3.83 | Influence of urate-lowering therapies on renal handling of uric acid. ( Chen, H; Ji, Z; Jiang, L; Ma, L; Wei, L; Yu, Q; Zhang, Z, 2016) |
| "The object of this study was to evaluate the effect of uric acid lowering therapy in reducing the new development of comorbidities and the frequency of acute attacks in gout patients." | 3.80 | Prevention of comorbidity and acute attack of gout by uric acid lowering therapy. ( Joo, H; Joo, K; Jung, KH; Kwon, SR; Lim, MJ; Park, W, 2014) |
| "Although hyperuricemia is suggested to increase allantoin production in both pro- and antioxidant manners, it remains undetermined whether it increases the serum concentration of allantoin." | 3.78 | Relationship between serum allantoin and urate in healthy subjects and effects of benzbromarone in gout patients. ( Koga, M; Koyama, H; Kurajoh, M; Moriwaki, Y; Shoji, T; Sumida, C; Tsutsumi, Z; Yamamoto, A; Yamamoto, T, 2012) |
| "A study was conducted to determine whether combination treatment using allopurinol and benzbromarone was more useful than single allopurinol treatment for the gout and hyperuricemia accompanying renal dysfunction." | 3.74 | [Usefulness of combination treatment using allopurinol and benzbromarone for gout and hyperuricemia accompanying renal dysfunction: kinetic analysis of oxypurinol]. ( Gomi, H; Hikita, M; Hosoya, T; Ichida, K; Ohno, I; Okabe, H; Saikawa, H; Uetake, D; Yamaguchi, Y, 2008) |
| "In 18 patients with monosodium urate (MSU) crystal proven gout, and after the initiation of successful serum uric acid (SUA)-lowering treatment, an arthrocentesis of the asymptomatic signal joint (11 knees, 7 first metatarsophalangeal joints) was performed every 3 months to obtain a synovial fluid (SF) sample." | 3.74 | Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. ( Pascual, E; Sivera, F, 2007) |
| "We measured serum concentrations of 1,25(OH)2-vitamin D3, 25(OH)-vitamin D3, parathyroid hormone (PTH), and uric acid in 114 male patients with primary gout and 51 normal male control subjects." | 3.70 | Decreased serum concentrations of 1,25(OH)2-vitamin D3 in patients with gout. ( Higashino, K; Moriwaki, Y; Takahashi, S; Tsutsumi, Z; Yamakita, J; Yamamoto, T, 1998) |
| "The results over 10 years in 200 patients (103 with gout and 97 with hyperuricaemia) treated with benzbromarone 75 - 120 mg/d are reported." | 3.66 | Ten years' experience with benzbromarone in the management of gout and hyperuricaemia. ( Giudicelli, CP; Masbernard, A, 1981) |
| " The drug is particularly useful in patients with chronic gouty arthritis and tophi, either refractory or allergic to probenecid, sulfinpyrazone, or allopurinol." | 3.65 | Pharmacokinetic and clinical studies of a new uricosuric agent - benzbromarone. ( Yu, TF, 1976) |
| "Three patients with gout and seven with hyperuricaemia, previously untreated, took a single dose of 100 mg allopurinol and 20 mg benzbromaron (as a combined preparation) each morning." | 3.65 | [Treatment of hyperuricaemia with a combination of allopurinol and benzbromaron (author's transl)]. ( Berg, G; Matzkies, F, 1976) |
"Treatment with benzbromarone monotherapy (range: 100-200 mg/day; mean 138 mg/day) resulted in 92% of patients reaching target levels sUr | 2.73 | Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients. ( Brouwers, JR; Houtman, PM; Jansen, TL; Reinders, MK; van Roon, EN, 2007) | |
| "Gout is a chronic inflammatory disease caused by precipitation of urate crystals in the joints, kidneys, and urinary tract." | 2.66 | Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia. ( Kuriyama, S, 2020) |
| " On the 5th and 6th day after beginning the treatment the dosage of 25 mg of Benzbromarone renders a morning value of 5,3 +/- 1,0 and an evening value of 5,0 +/- 0,9 mg/100 ml." | 2.64 | [Treatment of hyperuricemia using daily doses of 50 and 25mg of benzbromarone]. ( Berg, G; Matzkies, F; Minzlaff, R, 1977) |
| "Although gout is one of the most common forms of inflammatory arthritis, it has been relatively neglected until recently." | 2.55 | Major unanswered questions in the clinical gout field. ( Stamp, LK, 2017) |
| " Studies have identified the safe and effective dosing strategies for 'old' drugs such as allopurinol and colchicine." | 2.52 | Advances in pharmacotherapy for the treatment of gout. ( Dalbeth, N; Robinson, PC, 2015) |
| "Gout is a common disorder with clinical signs and symptoms resulting from inflammatory responses to monosodium urate crystals deposited in tissues from extracellular fluids saturated for urate." | 2.50 | Long-term management of gout: nonpharmacologic and pharmacologic therapies. ( Becker, MA; Chaichian, Y; Chohan, S, 2014) |
| "Gout is a crystal deposition disease." | 2.44 | [Establishment of therapeutic goal and plan of gout and asymptomatic hyperuricemia]. ( Fujimori, S, 2008) |
| "A major adverse effect of benzbromarone is hepatotoxicity." | 1.62 | Implementation Status of Liver Function Tests for Monitoring Benzbromarone-Induced Hepatotoxicity: An Epidemiological Survey Using the Japanese Claims Database. ( Imai, S; Kashiwagi, H; Miyai, T; Momo, K; Nasuhara, Y; Oki, H; Sato, Y; Sugawara, M; Takekuma, Y, 2021) |
| "Therefore, 35." | 1.51 | Nephrolithiasis in gout: prevalence and characteristics of Brazilian patients. ( Fuller, R; Goldenstein-Schainberg, C; Hoff, LS, 2019) |
| "Gout is independently associated with increased risk of type 2 diabetes mellitus (T2DM)." | 1.51 | Associations between urate-lowering therapy and the risk of type 2 diabetes mellitus. ( Chang, HW; Lan, YC; Lin, MH; Lin, YW; Wang, RY, 2019) |
| "First choice treatment of acute gout consists of NSAIDs." | 1.31 | [Summary of the Dutch College of General Practitioners' "Gout" Standard]. ( Gorter, KJ; Romeijnders, AC, 2002) |
| "Benzbromarone treatment, 50-100 mg daily, led to a parallel decrease of serum lipids and uric acid." | 1.28 | [The effect of benzbromarone on hyperlipidemia in gout]. ( Kŭnev, K; Marinchev, L, 1990) |
| "Uric acid clearance was increased by benzbromarone from 3." | 1.26 | [The effect of benzbromaron in gout patients with limited kidney function]. ( Bresnik, W; Kuzmits, R; Müller, MM, 1979) |
| "The incidence of gout has increased in recent years." | 1.26 | [Gout - a surgical problem]. ( Flügel, M; Geldmacher, J, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 37 (28.24) | 18.7374 |
| 1990's | 19 (14.50) | 18.2507 |
| 2000's | 21 (16.03) | 29.6817 |
| 2010's | 39 (29.77) | 24.3611 |
| 2020's | 15 (11.45) | 2.80 |
| Authors | Studies |
|---|---|
| Ichida, K | 2 |
| Hosoyamada, M | 1 |
| Kimura, H | 1 |
| Takeda, M | 1 |
| Utsunomiya, Y | 1 |
| Hosoya, T | 3 |
| Endou, H | 1 |
| Yang, X | 1 |
| Pang, X | 1 |
| Fan, L | 1 |
| Li, X | 2 |
| Chen, Y | 4 |
| Zhao, T | 2 |
| Meng, Q | 1 |
| Sun, Z | 1 |
| Ai, W | 1 |
| Zhao, Z | 1 |
| Kang, D | 1 |
| Dong, Y | 1 |
| Liang, R | 2 |
| Wu, T | 2 |
| Pang, J | 3 |
| Liu, X | 2 |
| Zhan, P | 2 |
| Zhang, J | 1 |
| Tao, Y | 1 |
| Liao, H | 1 |
| Zhao, F | 1 |
| Shi, X | 1 |
| Zhang, Z | 2 |
| Ji, J | 1 |
| Kang, EH | 1 |
| Park, EH | 1 |
| Shin, A | 1 |
| Song, JS | 1 |
| Kim, SC | 1 |
| Imai, S | 1 |
| Nasuhara, Y | 1 |
| Momo, K | 1 |
| Oki, H | 1 |
| Kashiwagi, H | 1 |
| Sato, Y | 1 |
| Miyai, T | 1 |
| Sugawara, M | 1 |
| Takekuma, Y | 1 |
| Lee, YH | 1 |
| Song, GG | 1 |
| Yan, F | 1 |
| Xue, X | 3 |
| Lu, J | 2 |
| Dalbeth, N | 5 |
| Qi, H | 1 |
| Yu, Q | 2 |
| Wang, C | 3 |
| Sun, M | 2 |
| Cui, L | 3 |
| Liu, Z | 2 |
| He, Y | 3 |
| Yuan, X | 2 |
| Cheng, X | 2 |
| Ma, L | 3 |
| Li, H | 2 |
| Ji, A | 3 |
| Hu, S | 1 |
| Ran, Z | 1 |
| Terkeltaub, R | 1 |
| Li, C | 3 |
| Sawada, S | 1 |
| Kajiyama, K | 1 |
| Shida, H | 1 |
| Kimura, R | 1 |
| Nakazato, Y | 1 |
| Iguchi, T | 1 |
| Oniyama, Y | 1 |
| Ishiguro, C | 1 |
| Uyama, Y | 1 |
| Lai, SW | 1 |
| Liao, KF | 1 |
| Kuo, YH | 1 |
| Hwang, BF | 1 |
| Liu, CS | 1 |
| Kawada, T | 1 |
| Azevedo, VF | 1 |
| Kos, IA | 1 |
| Vargas-Santos, AB | 1 |
| da Rocha Castelar Pinheiro, G | 1 |
| Dos Santos Paiva, E | 1 |
| Liang, N | 1 |
| Sun, R | 2 |
| Xu, T | 1 |
| Sun, W | 2 |
| Zhang, H | 2 |
| Wu, X | 1 |
| Chung, TT | 1 |
| Yu, KH | 1 |
| Kuo, CF | 1 |
| Luo, SF | 1 |
| Chiou, MJ | 1 |
| Lan, WC | 1 |
| Chen, JS | 1 |
| Tseng, WY | 1 |
| Hsieh, AH | 1 |
| Wang, LC | 1 |
| Kuriyama, S | 1 |
| Hoff, LS | 1 |
| Goldenstein-Schainberg, C | 1 |
| Fuller, R | 2 |
| Sano, T | 1 |
| Sasaki, T | 1 |
| Fushimi, M | 1 |
| Ohashi, T | 1 |
| Sakaguchi, S | 1 |
| Wang, X | 2 |
| Ren, W | 1 |
| Jia, Z | 1 |
| Ji, X | 1 |
| Merriman, TR | 2 |
| Pascart, T | 1 |
| Lefebvre, A | 1 |
| Ducoulombier, V | 1 |
| Becce, F | 1 |
| Budzik, JF | 1 |
| Tan, PK | 1 |
| Liu, S | 2 |
| Gunic, E | 1 |
| Miner, JN | 1 |
| Kim, JW | 1 |
| Kwak, SG | 1 |
| Park, SH | 1 |
| Wang, H | 1 |
| Peng, Y | 1 |
| Zhang, T | 1 |
| Lan, Q | 1 |
| Zhao, H | 1 |
| Wang, W | 1 |
| Zhao, Y | 1 |
| Wang, S | 1 |
| Zheng, J | 1 |
| Janssen, CA | 1 |
| Oude Voshaar, MAH | 1 |
| Vonkeman, HE | 1 |
| Krol, M | 1 |
| van de Laar, MAFJ | 1 |
| Niu, SW | 1 |
| Chang, KT | 1 |
| Ta, A | 1 |
| Chang, YH | 1 |
| Kuo, IC | 1 |
| Hung, CC | 1 |
| Chiu, YW | 1 |
| Hwang, SJ | 1 |
| Lin, SF | 1 |
| Lin, HY | 1 |
| Shiramoto, M | 1 |
| Shen, Z | 1 |
| Yan, X | 1 |
| Yamamoto, A | 4 |
| Gillen, M | 1 |
| Ito, Y | 1 |
| Hall, J | 1 |
| Jansen, TL | 4 |
| Perez-Ruiz, F | 5 |
| Tausche, AK | 2 |
| Richette, P | 1 |
| Chang, HW | 1 |
| Lin, YW | 1 |
| Lin, MH | 1 |
| Lan, YC | 1 |
| Wang, RY | 1 |
| Li, YJ | 1 |
| Perng, WT | 1 |
| Tseng, KY | 1 |
| Wang, YH | 1 |
| Wei, JC | 1 |
| Wu, J | 1 |
| Zhang, YP | 1 |
| Qu, Y | 1 |
| Jie, LG | 1 |
| Deng, JX | 1 |
| Yu, QH | 1 |
| Ellmann, H | 1 |
| Bayat, S | 1 |
| Araujo, E | 1 |
| Manger, B | 1 |
| Kleyer, A | 1 |
| Cavallaro, A | 1 |
| Lell, M | 1 |
| Schenker, H | 1 |
| Simon, D | 1 |
| Tascilar, K | 1 |
| Baraf, HSB | 1 |
| Schett, G | 1 |
| Rech, J | 1 |
| Roberts, RL | 1 |
| Wallace, MC | 1 |
| Wright, DF | 1 |
| Cadzow, M | 1 |
| Jones, PB | 1 |
| Stamp, LK | 3 |
| Harrison, AA | 1 |
| Black, MA | 1 |
| Mejía-Chew, C | 1 |
| Torres, RJ | 1 |
| de Miguel, E | 1 |
| Puig, JG | 1 |
| Gravatt, L | 1 |
| Day, R | 1 |
| Lee, H | 1 |
| Graham, G | 1 |
| Williams, K | 1 |
| Chaichian, Y | 1 |
| Chohan, S | 1 |
| Becker, MA | 1 |
| Joo, K | 1 |
| Kwon, SR | 1 |
| Lim, MJ | 1 |
| Jung, KH | 1 |
| Joo, H | 1 |
| Park, W | 1 |
| Seth, R | 2 |
| Kydd, AS | 2 |
| Buchbinder, R | 2 |
| Bombardier, C | 2 |
| Edwards, CJ | 2 |
| Wei, L | 1 |
| Chen, H | 1 |
| Ji, Z | 1 |
| Jiang, L | 1 |
| Robinson, PC | 1 |
| Füeßl, HS | 1 |
| Stiefelhagen, P | 1 |
| Haslett, J | 1 |
| Frampton, C | 1 |
| White, D | 1 |
| Gardner, D | 1 |
| Stebbings, S | 1 |
| Taylor, G | 1 |
| Grainger, R | 1 |
| Kumar, R | 1 |
| Kumar, S | 2 |
| Kain, T | 1 |
| Porter, D | 1 |
| Corkill, M | 1 |
| Cathro, A | 1 |
| Metcalfe, S | 1 |
| Wyeth, J | 1 |
| Zhou, Q | 1 |
| Su, J | 1 |
| Zhou, T | 1 |
| Tian, J | 1 |
| Chen, X | 1 |
| Zhu, J | 1 |
| Lin, HC | 1 |
| Daimon, M | 1 |
| Wang, CH | 1 |
| Ho, Y | 1 |
| Uang, YS | 1 |
| Chiang, SJ | 1 |
| Wang, LH | 1 |
| Ohno, I | 2 |
| Okabe, H | 1 |
| Yamaguchi, Y | 1 |
| Saikawa, H | 1 |
| Uetake, D | 1 |
| Hikita, M | 1 |
| Gomi, H | 1 |
| Reinders, MK | 3 |
| Haagsma, C | 1 |
| van Roon, EN | 3 |
| Delsing, J | 2 |
| van de Laar, MA | 2 |
| Brouwers, JR | 3 |
| Lee, MH | 1 |
| Graham, GG | 1 |
| Williams, KM | 1 |
| Day, RO | 1 |
| Inokuchi, T | 1 |
| Tsutsumi, Z | 5 |
| Takahashi, S | 3 |
| Ka, T | 1 |
| Moriwaki, Y | 5 |
| Masuzaki, H | 1 |
| Yamamoto, T | 5 |
| Hara, A | 1 |
| Mukae, H | 1 |
| Hara, S | 1 |
| Amenomori, M | 1 |
| Ishimoto, H | 1 |
| Kakugawa, T | 1 |
| Fujita, H | 1 |
| Sakamoto, N | 1 |
| Ishii, H | 1 |
| Ishimatsu, Y | 1 |
| Kohno, S | 1 |
| Hernandez-Baldizon, S | 1 |
| Herrero-Beites, AM | 3 |
| Gonzalez-Gay, MA | 1 |
| Doyle, A | 1 |
| McQueen, FM | 1 |
| Taniguchi, A | 1 |
| Okuda, C | 1 |
| Koyama, H | 2 |
| Kurajoh, M | 2 |
| Müller-Ladner, U | 1 |
| Panzner, I | 1 |
| Kriegsmann, J | 1 |
| Lange, U | 1 |
| Kao, JL | 1 |
| Hung, JJ | 1 |
| Huang, CH | 1 |
| Shiao, CC | 1 |
| Shoji, T | 1 |
| Sumida, C | 1 |
| Koga, M | 1 |
| Xiao, XY | 1 |
| Wang, YF | 1 |
| Xu, R | 1 |
| Hanvivadhanakul, P | 1 |
| Akkasilpa, S | 2 |
| Deesomchok, U | 2 |
| Calabozo, M | 3 |
| Pijoan, JI | 2 |
| Ruibal, A | 1 |
| Yamanaka, H | 2 |
| Boxberger, F | 1 |
| Harsch, IA | 1 |
| Brueckl, WM | 1 |
| Hautmann, M | 1 |
| Baum, U | 1 |
| Hahn, EG | 1 |
| Wein, A | 1 |
| Osiri, M | 1 |
| Avihingsanon, Y | 1 |
| Ng, J | 1 |
| Gow, P | 1 |
| Wong, ML | 1 |
| Caldas, CA | 1 |
| Pascual, E | 1 |
| Sivera, F | 1 |
| Houtman, PM | 1 |
| Griep, EN | 1 |
| Hoekstra, M | 1 |
| Fujimori, S | 2 |
| Mertz, DP | 6 |
| Eichhorn, R | 1 |
| Borner, K | 1 |
| Rodnan, GP | 1 |
| Matzkies, F | 8 |
| Heidelmann, G | 1 |
| Burck, G | 1 |
| Dauterstedt, W | 1 |
| Heinrich, JJ | 1 |
| Ohlmer, R | 1 |
| Kawenoki-Minc, E | 1 |
| Brzozowska-Jurkowska, AM | 2 |
| Bluestone, R | 1 |
| Klinenberg, J | 1 |
| Lee, IK | 1 |
| Ferber, H | 1 |
| Bader, U | 1 |
| Dorn, M | 1 |
| Masbernard, A | 1 |
| Giudicelli, CP | 1 |
| Levinson, DJ | 2 |
| Sorensen, LB | 2 |
| Jelke, K | 1 |
| Neubauer, M | 1 |
| Krause, G | 1 |
| Jüttner, A | 1 |
| Angar, T | 1 |
| Grosse-Kielisch, C | 1 |
| Bach, GL | 1 |
| Kaneko, K | 1 |
| Akaoka, I | 3 |
| Gresser, U | 2 |
| Gathof, BS | 1 |
| Gross, M | 1 |
| Balkarov, IM | 1 |
| Müller, FO | 1 |
| Schall, R | 1 |
| Groenewoud, G | 1 |
| Hundt, HK | 1 |
| van der Merwe, JC | 1 |
| van Dyk, M | 1 |
| Hisatome, I | 1 |
| Kosaka, H | 1 |
| Ohtahara, K | 1 |
| Tsuboi, M | 1 |
| Manabe, I | 1 |
| Ohtahara, A | 1 |
| Sawaguchi, M | 1 |
| Igawa, O | 1 |
| Tanaka, Y | 1 |
| Fujimoto, Y | 1 |
| Yoshida, A | 1 |
| Takeda, A | 1 |
| Shigemasa, C | 1 |
| Toda, K | 1 |
| Goriki, K | 1 |
| Ochiai, M | 1 |
| Tokunou, H | 1 |
| Uehara, S | 1 |
| Takahashi, H | 1 |
| Okusaki, K | 1 |
| Yamakita, J | 2 |
| Higashino, K | 2 |
| Grahame, R | 1 |
| Simmonds, HA | 1 |
| McBride, MB | 1 |
| Marsh, FP | 1 |
| Lhotta, K | 1 |
| Gruber, J | 1 |
| Sgonc, R | 1 |
| Fend, F | 1 |
| König, P | 1 |
| Decaux, G | 1 |
| Soupart, A | 1 |
| Musch, W | 1 |
| Hannotier, P | 1 |
| Prospert, F | 1 |
| Alonso-Ruiz, A | 1 |
| Herrero-Beites, A | 1 |
| García-Erauskin, G | 2 |
| Ruiz-Lucea, E | 1 |
| Chazerain, P | 1 |
| Ziza, JM | 1 |
| Gröbner, W | 1 |
| Walter-Sack, I | 1 |
| Romeijnders, AC | 1 |
| Gorter, KJ | 1 |
| Berg, G | 3 |
| Minzlaff, R | 1 |
| Heel, RC | 1 |
| Brogden, RN | 1 |
| Speight, TM | 1 |
| Avery, GS | 1 |
| Bosmanský, K | 1 |
| Trnavský, K | 1 |
| König, HJ | 1 |
| Kuzmits, R | 1 |
| Bresnik, W | 1 |
| Müller, MM | 1 |
| Barsom, S | 1 |
| Nishizawa, T | 2 |
| Nishida, Y | 2 |
| Masuda, T | 2 |
| Flügel, M | 1 |
| Geldmacher, J | 1 |
| Bröll, H | 1 |
| Sochor, H | 1 |
| Tausch, G | 1 |
| Eberl, R | 1 |
| Stuhlsatz, HW | 1 |
| Enzensberger, W | 1 |
| Greiling, H | 1 |
| Neuwirth, R | 1 |
| Yu, TF | 1 |
| Sinclair, DS | 1 |
| Fox, IH | 1 |
| Schräpler, P | 1 |
| Schulz, E | 1 |
| Siegenthaler-Zuber, G | 1 |
| Marinchev, L | 1 |
| Kŭnev, K | 1 |
| Berg, H | 1 |
| Hess, B | 1 |
| Binswanger, U | 1 |
| Imanishi, M | 1 |
| Ikegami, M | 1 |
| Ishii, T | 1 |
| Nishioka, T | 1 |
| Uemura, T | 1 |
| Kunikata, S | 1 |
| Kanda, H | 1 |
| Matsuura, T | 1 |
| Akiyama, T | 1 |
| Kurita, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 for Hyperuricemia With or Without Gout to Evaluate the Safety and Noninferiority of FYU-981 (Phase III Study)[NCT03100318] | Phase 3 | 201 participants (Actual) | Interventional | 2017-04-01 | Completed | ||
| A Phase 2a, Randomized, Open-Label, Single-Site Study to Evaluate the Pharmacodynamic Effects and Safety of RDEA3170 Administered in Combination With Febuxostat Compared to RDEA3170 Administered Alone and Febuxostat Administered Alone, Respectively in Jap[NCT02317861] | Phase 1/Phase 2 | 110 participants (Actual) | Interventional | 2014-12-31 | Completed | ||
| Allopurinol in the Treatment of Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Treated by Either PCI or CABG: Pilot Study[NCT03700645] | Phase 4 | 100 participants (Anticipated) | Interventional | 2018-12-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
18 reviews available for benzbromarone and Gout
| Article | Year |
|---|---|
Comparative efficacy and safety of dotinurad, febuxostat, and benzbromarone in hyperuricemic patients with or without gout: A network meta-analysis of randomized controlled trials.
Topics: Benzbromarone; Benzothiazoles; Febuxostat; Gout; Gout Suppressants; Humans; Network Meta-Analysis; R | 2022 |
Benzbromarone in the treatment of gout.
Topics: Benzbromarone; Cytochrome P-450 CYP2C9; Gout; Humans; In Vitro Techniques; Liver; Mitochondria, Live | 2019 |
Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Benzbromarone; Benzothiazoles; Drug Interactions; Febuxosta | 2020 |
International position paper on the appropriate use of uricosurics with the introduction of lesinurad.
Topics: Benzbromarone; Europe; Febuxostat; Gout; Humans; International Cooperation; Practice Guidelines as T | 2018 |
Long-term management of gout: nonpharmacologic and pharmacologic therapies.
Topics: Allopurinol; Benzbromarone; Chronic Disease; Febuxostat; Feeding Behavior; Gout; Gout Suppressants; | 2014 |
Allopurinol for chronic gout.
Topics: Allopurinol; Benzbromarone; Chronic Disease; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans | 2014 |
Uricosuric medications for chronic gout.
Topics: Adult; Aged; Allopurinol; Benzbromarone; Chronic Disease; Controlled Clinical Trials as Topic; Femal | 2014 |
Advances in pharmacotherapy for the treatment of gout.
Topics: Adrenal Cortex Hormones; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclona | 2015 |
Major unanswered questions in the clinical gout field.
Topics: Allopurinol; Benzbromarone; Colchicine; Disease Progression; Febuxostat; Gout; Gout Suppressants; Hu | 2017 |
A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?
Topics: Animals; Benzbromarone; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Drug Appro | 2008 |
[Treatment of hyperuricemia and gout based on the guideline for the management of hyperuricemia and gout].
Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Benzbromarone; Colchicine; Glucocorticoids; Go | 2010 |
[Gout - regardless of therapeutic options a "forgotten" disease].
Topics: Allopurinol; Arthritis, Gouty; Benzbromarone; Combined Modality Therapy; Cytokines; Europe; Febuxost | 2011 |
[Drug therapy for idiopathic hyperuricemia--introduction, dose, and side effects].
Topics: Allopurinol; Arteriosclerosis; Benzbromarone; Enzyme Inhibitors; Gout; Humans; Hyperuricemia; Kidney | 2003 |
[Establishment of therapeutic goal and plan of gout and asymptomatic hyperuricemia].
Topics: Allopurinol; Benzbromarone; Cardiovascular Diseases; Gout; Gout Suppressants; Humans; Hyperuricemia; | 2008 |
[Uricosuric agent].
Topics: Allopurinol; Benzbromarone; Gout; Humans; Hyperuricemia; Kidney Tubules, Proximal; Organic Anion Tra | 2008 |
Treatment of the gout and other forms of crystal-induced arthritis.
Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Benzbromarone; Colchicine; Gout; Go | 1982 |
[Benzbromarone in the treatment of gout].
Topics: Benzbromarone; Benzofurans; Biological Availability; Chemical Phenomena; Chemistry; Gout; Half-Life; | 1980 |
Benzbromarone: a review of its pharmacological properties and therapeutic use in gout and hyperuricaemia.
Topics: Aspirin; Benzbromarone; Benzofurans; Drug Interactions; Fasting; Gout; Humans; Kidney Diseases; Kine | 1977 |
30 trials available for benzbromarone and Gout
| Article | Year |
|---|---|
Superiority of Low-Dose Benzbromarone to Low-Dose Febuxostat in a Prospective, Randomized Comparative Effectiveness Trial in Gout Patients With Renal Uric Acid Underexcretion.
Topics: Allopurinol; Benzbromarone; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Prospe | 2022 |
Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort.
Topics: Benzbromarone; Biomarkers; China; Dose-Response Relationship, Drug; Febuxostat; Follow-Up Studies; G | 2019 |
Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study.
Topics: Adult; Aged; Benzbromarone; Benzothiazoles; Double-Blind Method; Female; Gout; Humans; Hyperuricemia | 2020 |
The efficacy and safety of citrate mixture vs sodium bicarbonate on urine alkalization in Chinese primary gout patients with benzbromarone: a prospective, randomized controlled study.
Topics: Adult; Benzbromarone; China; Citrates; Drug Administration Schedule; Glomerular Filtration Rate; Gou | 2021 |
Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study.
Topics: Administration, Oral; Adult; Aged; Benzbromarone; Dose-Response Relationship, Drug; Drug Therapy, Co | 2018 |
Allopurinol, benzbromarone and risk of coronary heart disease in gout patients: A population-based study.
Topics: Allopurinol; Benzbromarone; Coronary Disease; Dose-Response Relationship, Drug; Drug Administration | 2017 |
A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout.
Topics: Aged; Allopurinol; Benzbromarone; Confidence Intervals; Dose-Response Relationship, Drug; Drug Admin | 2009 |
Effects of benzbromarone and allopurinol on adiponectin in vivo and in vitro.
Topics: 3T3-L1 Cells; Adiponectin; Adult; Allopurinol; Animals; Benzbromarone; Gene Expression; Gout; Humans | 2009 |
Serum CRP in patients with gout and effects of benzbromarone.
Topics: Adiponectin; Adult; Benzbromarone; C-Reactive Protein; Case-Control Studies; Cell Line, Tumor; Gene | 2011 |
[Stage-based treatment of integrative medicine on the quality of life in patients with gout].
Topics: Adult; Aged; Aged, 80 and over; Benzbromarone; Diclofenac; Drugs, Chinese Herbal; Female; Gout; Huma | 2012 |
Efficacy of benzbromarone compared to allopurinol in lowering serum uric acid level in hyperuricemic patients.
Topics: Adult; Aged; Allopurinol; Benzbromarone; Cross-Over Studies; Dose-Response Relationship, Drug; Drug | 2002 |
Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.
Topics: Adult; Aged; Allopurinol; Benzbromarone; Crystallization; Drug Therapy, Combination; Female; Gout; G | 2002 |
Benzbromarone therapy in management of refractory gout.
Topics: Adult; Allopurinol; Benzbromarone; Creatinine; Female; Gout; Humans; Incidence; Male; Metabolic Clea | 2005 |
Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients.
Topics: Allopurinol; Benzbromarone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Gou | 2007 |
Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.
Topics: Aged; Allopurinol; Benzbromarone; Confidence Intervals; Dose-Response Relationship, Drug; Drug Admin | 2009 |
[Excretion and serum concentrations of allopurinol, oxipurinol and oxipurines in combined treatment with allopurinol and benzbromarone in increasing doses].
Topics: Adult; Aged; Allopurinol; Benzbromarone; Benzofurans; Dose-Response Relationship, Drug; Drug Therapy | 1983 |
[Effect of benziodarone and benzbromarone on the uric acid level in the blood and urine and on the incidence of gout attacks].
Topics: Adult; Aged; Benzbromarone; Benzofurans; Clinical Trials as Topic; Gout; Humans; Male; Middle Aged; | 1980 |
Benzbromarone as a long-term uricosuric agent.
Topics: Benzbromarone; Benzofurans; Clinical Trials as Topic; Follow-Up Studies; Gout; Humans; Uric Acid | 1980 |
The action of benzbromarone in relation to age, sex and accompanying diseases.
Topics: Benzbromarone; Benzofurans; Body Height; Body Weight; Clinical Trials as Topic; Female; Follow-Up St | 1980 |
[The effect on uric acid and other laboratory parameters. A long-term study].
Topics: Allopurinol; Benzbromarone; Benzofurans; Clinical Trials as Topic; Gout; Humans; Uric Acid | 1982 |
Effect of hypouricemic agents on serum carbohydrate-deficient transferrin in gouty patients.
Topics: Adult; Aged; Aged, 80 and over; Alcohol Drinking; Allopurinol; Benzbromarone; Chromatography, Ion Ex | 1994 |
The effect of benzbromarone on allopurinol/oxypurinol kinetics in patients with gout.
Topics: Adult; Aged; Allopurinol; Benzbromarone; Gout; Humans; Male; Middle Aged; Oxypurinol; Uric Acid | 1993 |
Effect of allopurinol and benzbromarone on the concentration of uridine in plasma.
Topics: Adult; Allopurinol; Benzbromarone; Dose-Response Relationship, Drug; Gout; Gout Suppressants; Humans | 1997 |
Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout.
Topics: Adult; Aged; Allopurinol; Benzbromarone; Chronic Disease; Drug Administration Schedule; Gout; Gout S | 1998 |
Improvement of renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts.
Topics: Adult; Aged; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Benzbromarone; Creatinine; Drug T | 2000 |
[Treatment of hyperuricemia using daily doses of 50 and 25mg of benzbromarone].
Topics: Benzbromarone; Clinical Trials as Topic; Drug Evaluation; Gout; Humans; Male; Uric Acid | 1977 |
[Reducing the risks in the treatment of gout and hyperuricaemia (author's transl)].
Topics: Adult; Allopurinol; Benzbromarone; Benzofurans; Clinical Trials as Topic; Drug Combinations; Female; | 1976 |
[Therapy with alllopurinol and benzbromarone, single and combined. Renal elimination of lithogenous and colloid protective substances (author's transl)].
Topics: Adult; Aged; Allopurinol; Benzbromarone; Benzofurans; Calcium; Citrates; Creatinine; Glomerular Filt | 1977 |
[Pathogenesis and treatment of fast-induced hyperuricemia using benzbromarone].
Topics: Adolescent; Adult; Benzbromarone; Benzofurans; Fasting; Female; Gout; Humans; Male; Middle Aged; Sta | 1976 |
[Effectiveness and tolerance of long-term uricosuric treatment].
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Benzbromarone; Dose-Response Relationship, Drug; Drug C | 1990 |
83 other studies available for benzbromarone and Gout
| Article | Year |
|---|---|
Urate transport via human PAH transporter hOAT1 and its gene structure.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Benzbromarone; Biological Transport; Blotting, Western; Car | 2003 |
Synthesis and evaluation of sulfonamide derivatives as potent Human Uric Acid Transporter 1 (hURAT1) inhibitors.
Topics: Animals; Gout; Gout Suppressants; Humans; Male; Organic Anion Transporters; Organic Cation Transport | 2017 |
Novel Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Favorable Druggability.
Topics: Animals; Carbon-13 Magnetic Resonance Spectroscopy; Gout; HEK293 Cells; Humans; Hyperuricemia; Mass | 2020 |
Discovery of Novel Bicyclic Imidazolopyridine-Containing Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Improved Efficacy and Favorable Druggability.
Topics: Animals; Gout; Humans; Hyperuricemia; Mice; Organic Anion Transporters; Organic Cation Transport Pro | 2022 |
Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout.
Topics: Allopurinol; Benzbromarone; Cardiovascular Diseases; Cohort Studies; Gout; Gout Suppressants; Heart | 2021 |
Implementation Status of Liver Function Tests for Monitoring Benzbromarone-Induced Hepatotoxicity: An Epidemiological Survey Using the Japanese Claims Database.
Topics: Administrative Claims, Healthcare; Adolescent; Adult; Aged; Benzbromarone; Chemical and Drug Induced | 2021 |
Cardiovascular risk of urate-lowering drugs: A study using the National Database of Health Insurance Claims and Specific Health Checkups of Japan.
Topics: Allopurinol; Benzbromarone; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Heart Dise | 2023 |
The risk of ischemic cerebrovascular disease associated with benzbromarone use in gout people: A retrospective cohort study in Taiwan.
Topics: Benzbromarone; Cerebrovascular Disorders; Gout; Gout Suppressants; Humans; Retrospective Studies; Ta | 2023 |
Superiority of low-dose benzbromarone to low-dose febuxostat in gout patients with renal uric acid underexcretion: comment on the article by Yan et al.
Topics: Allopurinol; Benzbromarone; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Ou | 2023 |
Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients.
Topics: Allopurinol; Benzbromarone; Disease Progression; Febuxostat; Female; Glomerular Filtration Rate; Gou | 2019 |
Nephrolithiasis in gout: prevalence and characteristics of Brazilian patients.
Topics: Adult; Asymptomatic Diseases; Benzbromarone; Brazil; Cross-Sectional Studies; Diabetes Mellitus; Diu | 2019 |
Repair of Bone Erosion With Effective Urate-Lowering Therapy in a Patient With Tophaceous Gout.
Topics: Benzbromarone; Bone Resorption; Enzyme Inhibitors; Gout; Humans; Male; Metatarsal Bones; Metatarsoph | 2021 |
Drastic monosodium urate crystal dissolution with febuxostat and benzbromarone.
Topics: Allopurinol; Benzbromarone; Febuxostat; Gout; Gout Suppressants; Humans; Solubility; Uric Acid | 2021 |
Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout.
Topics: Adult; Animals; Benzbromarone; Biological Transport; Dose-Response Relationship, Drug; Gout; HEK293 | 2017 |
Prescription pattern of urate-lowering therapy in Korean gout patients: data from the national health claims database.
Topics: Allopurinol; Benzbromarone; Databases, Factual; Febuxostat; Gout; Gout Suppressants; Humans; Republi | 2018 |
Metabolic Epoxidation Is a Critical Step for the Development of Benzbromarone-Induced Hepatotoxicity.
Topics: Activation, Metabolic; Animals; Benzbromarone; Chemical and Drug Induced Liver Injury; Cytochrome P- | 2017 |
A retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperuricemia in The Netherlands.
Topics: Adult; Aged; Allopurinol; Benzbromarone; Febuxostat; Female; General Practitioners; Gout; Gout Suppr | 2018 |
Decreased incidence of diabetes in patients with gout using benzbromarone.
Topics: Adult; Benzbromarone; Comorbidity; Diabetes Mellitus; Disease Progression; Dose-Response Relationshi | 2018 |
Associations between urate-lowering therapy and the risk of type 2 diabetes mellitus.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Allopurinol; Benzbromarone; Case-Control Studies; Diabe | 2019 |
Association of gout medications and risk of cataract: a population-based case-control study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Allopurinol; Benzbromarone; Case-Control Studies; Catar | 2019 |
Efficacy of uric acid-lowering therapy on hypercholesterolemia and hypertriglyceridemia in gouty patients.
Topics: Adult; Allopurinol; Benzbromarone; Biomarkers; Cholesterol; Febuxostat; Female; Gout; Gout Suppressa | 2019 |
Effects of Conventional Uric Acid-Lowering Therapy on Monosodium Urate Crystal Deposits.
Topics: Aged; Alcohol Drinking; Allopurinol; Benzbromarone; Diet Therapy; Febuxostat; Female; Foot Joints; F | 2020 |
Frequency of CYP2C9 polymorphisms in Polynesian people and potential relevance to management of gout with benzbromarone.
Topics: Aryl Hydrocarbon Hydroxylases; Benzbromarone; Cytochrome P-450 CYP2C9; Gout; Gout Suppressants; Huma | 2014 |
Resolution of massive tophaceous gout with three urate-lowering drugs.
Topics: Allopurinol; Benzbromarone; Colchicine; Drug Therapy, Combination; Gout; Gout Suppressants; Humans; | 2013 |
Gout--is Lee's 2008 risk:benefit conclusion for benzbromarone hepatotoxicity still relevant today?
Topics: Animals; Benzbromarone; Gout; Humans; Uricosuric Agents | 2013 |
Benzbromarone: availability for general prescribing in New Zealand (a response to letters by Dr Lance Gravatt onbenzbromarone).
Topics: Animals; Benzbromarone; Cardiovascular Diseases; Diabetes Mellitus; Female; Gout; Humans; Male; Uric | 2013 |
Prevention of comorbidity and acute attack of gout by uric acid lowering therapy.
Topics: Adult; Allopurinol; Antimetabolites; Benzbromarone; Cardiovascular Diseases; Comorbidity; Diabetes M | 2014 |
Influence of urate-lowering therapies on renal handling of uric acid.
Topics: Adult; Antihypertensive Agents; Benzbromarone; Case-Control Studies; Creatinine; Glomerular Filtrati | 2016 |
[Using the whole arsenal to prevent an attack].
Topics: Allopurinol; Arthritis, Gouty; Benzbromarone; Combined Modality Therapy; Febuxostat; Female; Gout; G | 2015 |
The safety and efficacy of benzbromarone in gout in Aotearoa New Zealand.
Topics: Aged; Allopurinol; Benzbromarone; Comorbidity; Exanthema; Female; Gout; Gout Suppressants; Humans; K | 2016 |
A study comparing the safety and efficacy of febuxostat, allopurinol, and benzbromarone in Chinese gout patients: a retrospective cohort study
.
Topics: Adult; Allopurinol; Asian People; Benzbromarone; Biomarkers; China; Drug Dosage Calculations; Febuxo | 2017 |
[Usefulness of combination treatment using allopurinol and benzbromarone for gout and hyperuricemia accompanying renal dysfunction: kinetic analysis of oxypurinol].
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Benzbromarone; Drug Therapy, Combination; Gout; Gout Su | 2008 |
Drug-induced eosinophilic pneumonia with pulmonary alveolar hemorrhage caused by benzbromarone.
Topics: Benzbromarone; Bronchoalveolar Lavage Fluid; Gout; Hemorrhage; Humans; Lung; Lung Diseases; Male; Mi | 2010 |
Risk factors associated with renal lithiasis during uricosuric treatment of hyperuricemia in patients with gout.
Topics: Allopurinol; Benzbromarone; Cohort Studies; Creatinine; Follow-Up Studies; Gout; Humans; Hyperuricem | 2010 |
Clinical images: Divergent patterns of joint remodeling following effective urate-lowering therapy in tophaceous gout.
Topics: Adult; Allopurinol; Arthrography; Benzbromarone; Finger Joint; Gout; Gout Suppressants; Humans; Hype | 2011 |
Giant tophi in the calf.
Topics: Adult; Benzbromarone; Gout; Humans; Leg; Male; Radiography | 2012 |
Relationship between serum allantoin and urate in healthy subjects and effects of benzbromarone in gout patients.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Allantoin; Benzbromarone; Biomarkers; Case-Control Studies; Crea | 2012 |
[Chronic gout. Case report of a severe course of disease].
Topics: Adult; Allopurinol; Benzbromarone; Chronic Disease; Drug Therapy, Combination; Gout; Gout Suppressan | 2003 |
The efficacy of combined low dose of Allopurinol and benzbromarone compared to standard dose of Allopurinol in hyperuricemia.
Topics: Allopurinol; Benzbromarone; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug The | 2004 |
Optimal management of chronic gout: attempting to render the (t)issues crystal-clear.
Topics: Allopurinol; Anti-Inflammatory Agents; Benzbromarone; Chronic Disease; Colchicine; Drug Hypersensiti | 2005 |
Excellent response to the clinical treatment of tophaceous gout.
Topics: Aged; Allopurinol; Benzbromarone; Glomerular Filtration Rate; Gout; Gout Suppressants; Humans; Kidne | 2007 |
Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout.
Topics: Adult; Aged; Benzbromarone; Chronic Disease; Crystallization; Follow-Up Studies; Gout; Gout Suppress | 2007 |
Does benzbromarone in therapeutic doses raise renal excretion of oxipurinol?
Topics: Adult; Aged; Allopurinol; Benzbromarone; Benzofurans; Creatinine; Drug Therapy, Combination; Glomeru | 1984 |
[Current therapy: combined drug therapy of hyperuricemia, gout and alcohol induced fatty liver].
Topics: Allopurinol; Benzbromarone; Benzofurans; Drug Therapy, Combination; Fatty Liver, Alcoholic; Gout; Hu | 1983 |
[Therapy of hyperuricemia and gout. Effect of a combination therapy of allopurinol with benzbromarone].
Topics: Allopurinol; Benzbromarone; Benzofurans; Chemical Phenomena; Chemistry; Drug Therapy, Combination; G | 1983 |
[Indications for and methods of allopurinol-benzbromarone combination therapy in the treatment of hyperuricemic metabolic disorders].
Topics: Adult; Aged; Allopurinol; Benzbromarone; Benzofurans; Drug Interactions; Drug Therapy, Combination; | 1982 |
Ten years' experience with benzbromarone in the management of gout and hyperuricaemia.
Topics: Adult; Aged; Benzbromarone; Benzofurans; Female; Follow-Up Studies; Gout; Humans; Male; Middle Aged; | 1981 |
[Uric acid-induced diseases. 2. Therapy].
Topics: Allopurinol; Benzbromarone; Benzothiadiazines; Diuretics; Gout; Humans; Purines; Sodium Chloride Sym | 1980 |
Renal handling of uric acid in normal and gouty subject: evidence for a 4-component system.
Topics: Absorption; Benzbromarone; Blood Proteins; Female; Gout; Humans; In Vitro Techniques; Kidney; Kidney | 1980 |
[Efficacy and tolerance of a new benzbromarone preparation].
Topics: Benzbromarone; Benzofurans; Gout; Humans; Hydrogen-Ion Concentration; Uric Acid; Urine | 1980 |
Determination of tubular secretion of urate in healthy and gouty men.
Topics: Adult; Benzbromarone; Female; Gout; Humans; Kidney Tubules; Male; Reference Values; Uric Acid | 1980 |
Benzbromarone and fenofibrate are lipid lowering and uricosuric: a possible key to metabolic syndrome?
Topics: Benzbromarone; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Fenofibrate; Gout; Humans; Hyperlipi | 1994 |
[The use of Allomaron in treating hyperuricemia].
Topics: Adult; Allopurinol; Arthritis, Gouty; Benzbromarone; Creatinine; Drug Combinations; Drug Evaluation; | 1994 |
Renal handling of urate in a patient with familial juvenile gouty nephropathy.
Topics: Adolescent; Benzbromarone; Female; Genes, Dominant; Gout; Gout Suppressants; Humans; Kidney; Kidney | 1996 |
Gout due to xanthine derivatives.
Topics: Allopurinol; Aminophylline; Asthma; Benzbromarone; Bronchodilator Agents; Drug Therapy, Combination; | 1997 |
Decreased serum concentrations of 1,25(OH)2-vitamin D3 in patients with gout.
Topics: Adult; Allopurinol; Benzbromarone; Calcifediol; Calcitriol; Calcium; Gout; Gout Suppressants; Humans | 1998 |
How should we treat tophaceous gout in patients with allopurinol hypersensitivity?
Topics: Adolescent; Adult; Aged; Allopurinol; Benzbromarone; Creatinine; Drug Hypersensitivity; Gout; Gout S | 1998 |
Apoptosis of tubular epithelial cells in familial juvenile gouty nephropathy.
Topics: Adult; Apoptosis; Benzbromarone; Biopsy; Biotin; Deoxyuracil Nucleotides; DNA Fragmentation; Family | 1998 |
Restoration of the uricosuric effect of probenecid after triglycylvasopressine administration in a gouty patient.
Topics: Absorption; Acute Kidney Injury; Adult; Anti-Inflammatory Agents; Benzbromarone; Fludrocortisone; Go | 1998 |
[Gout: physiopathology, diagnosis, course, treatment].
Topics: Adult; Aged; Allopurinol; Arthritis, Gouty; Benzbromarone; Diagnosis, Differential; Female; Gout; Go | 1998 |
[Hyperuricemia and gout--treatment].
Topics: Acute Disease; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Benzbromarone; Colchicine; Drug | 2002 |
[Summary of the Dutch College of General Practitioners' "Gout" Standard].
Topics: Acute Disease; Adrenal Cortex Hormones; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Benzbr | 2002 |
[Treating gout with benzbromarone (author's transl)].
Topics: Adult; Aged; Benzbromarone; Benzofurans; Female; Gout; Humans; Male; Middle Aged | 1979 |
[Therapy of gout].
Topics: Allopurinol; Arteriosclerosis; Benzbromarone; Colchicine; Gout; Humans; Immobilization; Indomethacin | 1979 |
[The effect of benzbromaron in gout patients with limited kidney function].
Topics: Adult; Aged; Benzbromarone; Benzofurans; Creatinine; Drug Evaluation; Gout; Humans; Kidney Diseases; | 1979 |
[Allomaron in hyperuricemia and gout].
Topics: Adolescent; Adult; Aged; Allopurinol; Benzbromarone; Benzofurans; Drug Combinations; Drug Evaluation | 1979 |
[Treatment of gout with alternate-day antihyperuricemic drugs (author's transl)].
Topics: Adult; Aged; Benzbromarone; Drug Administration Schedule; Female; Gout; Humans; Male; Middle Aged; U | 1978 |
[Effects and side effects of benzbromaron in the initial treatment of hyperuricemia and gout. Results of a field study on 3899 patients].
Topics: Benzbromarone; Benzofurans; Diarrhea; Female; Gout; Humans; Kidney Calculi; Male; Nausea; Uric Acid | 1978 |
[Gout - a surgical problem].
Topics: Allopurinol; Benzbromarone; Female; Gout; Hand; Humans; Middle Aged; Patient Care Team; Uric Acid | 1978 |
Treatment of gout with alternate-day hypo-uricaemic drugs.
Topics: Adult; Aged; Allopurinol; Benzbromarone; Benzofurans; Female; Gout; Humans; Male; Middle Aged; Sulfi | 1978 |
[Long-term therapy with benzbromarone in uric arthritis].
Topics: Adult; Aged; Benzbromarone; Benzofurans; Diarrhea; Female; Gout; Humans; Leukopenia; Long-Term Care; | 1975 |
Protein binding to monosodium urate crystals and its effect on platelet degranulation. Influence of urate on connective tissue metabolism.
Topics: Acetylglucosaminidase; Benzbromarone; Connective Tissue; Glycosaminoglycans; Gout; Heparin; Hyaluron | 1977 |
[Isolated or combined drug therapy of hyperuricemia?].
Topics: Allopurinol; Benzbromarone; Drug Therapy, Combination; Gout; Humans; Uric Acid; Uricosuric Agents | 1977 |
[Serum uric acid and uric acid elimination after benzbromarone therapy in patients with gout and hyperuricemia].
Topics: Benzbromarone; Benzofurans; Gout; Humans; Uric Acid | 1976 |
Pharmacokinetic and clinical studies of a new uricosuric agent - benzbromarone.
Topics: Adult; Aged; Arthritis; Benzbromarone; Benzofurans; Chemical Phenomena; Chemistry; Chronic Disease; | 1976 |
[Treatment of hyperuricaemia with a combination of allopurinol and benzbromaron (author's transl)].
Topics: Allopurinol; Benzbromarone; Benzofurans; Drug Combinations; Gout; Humans; Time Factors; Uric Acid | 1976 |
The pharmacology of hypouricemic effect of benzbromarone.
Topics: Adult; Aspirin; Benzbromarone; Benzofurans; Blood Proteins; Creatinine; Female; Gout; Humans; Male; | 1975 |
[Which uric acid value is in need of treatment?].
Topics: Allopurinol; Benzbromarone; Citrates; Coronary Disease; Gout; Humans; Hyperlipidemias; Hypertension; | 1976 |
[Long lasting normalization of uric acid after combination therapy with 300 mg allopurinol and 60 mg benzbromarone in patients with gout and hyperuricemia].
Topics: Allopurinol; Benzbromarone; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug The | 1992 |
[Uric acid level in blood donors of southern Germany--almost constant since 1971].
Topics: Adult; Arthritis, Gouty; Benzbromarone; Benzimidazoles; Blood Donors; Cross-Sectional Studies; Femal | 1991 |
[The effect of benzbromarone on hyperlipidemia in gout].
Topics: Adult; Benzbromarone; Drug Evaluation; Gout; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; | 1990 |
Acute uric acid nephropathy in two gouty patients with moderate hyperuricemia and high urine acidity.
Topics: Acute Kidney Injury; Benzbromarone; Glomerular Filtration Rate; Gout; Humans; Male; Middle Aged; Uri | 1990 |
[Clinical studies on hyperuricemia and gout after transplantation].
Topics: Adult; Allopurinol; Analgesics; Benzbromarone; Female; Gout; Humans; Immunosuppressive Agents; Kidne | 1990 |